Subscribe
shutterstock_2162525475_jonathan-weiss
shutterstock_2162525475_jonathan-weiss
4 October 2022Big PharmaStaff writer

SCOTUS invites govt comment on Teva clash

The US Supreme Court has asked the US government to weigh in on whether the court should hear the ‘skinny-label’ dispute between Teva and GSK.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Teva takes long-running ‘skinny label’ suit to SCOTUS
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Teva takes long-running ‘skinny label’ suit to SCOTUS
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

More on this story

Americas
Teva takes long-running ‘skinny label’ suit to SCOTUS
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York